Vascular Aging and Microcirculation: Physiological Aspects of Vascular Aging in the Elderly Popul… (NCT07563725) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Vascular Aging and Microcirculation: Physiological Aspects of Vascular Aging in the Elderly Population (VAMP-Aging)
Brazil62 participantsStarted 2026-06
Plain-language summary
Rising life expectancy worldwide challenges public health due to increased cardiovascular disease linked to vascular aging, where microvascular dysfunction serves as an early indicator of system-wide inflammation, or "inflammaging". The proposed study aims to validate non-invasive, high-resolution techniques, such as Laser Speckle Contrast Imaging, to identify early endothelial senescence biomarkers and map their correlation with metabolic, inflammatory, and anthropometric profiles to advance personalized, preventive translational medicine.
Who can participate
Age range
60 Years – 100 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Absence of symptoms and history of cardiovascular and cerebrovascular diseases.
* Baseline blood pressure levels within the normal range (\< 140/90 mmHg, according to WHO criteria) and absence of use of antihypertensive medications.
Exclusion Criteria:
* Diabetes Mellitus: Fasting blood glucose ≥ 126 mg/dL or use of hypoglycemic agents.
* Smoking: Active or quit less than 5 years ago.
* Inflammatory Diseases: Autoimmune diseases, active neoplasms, or acute infectious processes.
* Surgery or trauma in the last 60 days.
* Renal Dysfunction: Chronic renal failure (estimated by eGFR \< 60 mL/min/1.73m²).
* Medication Use: Chronic use of corticosteroids, immunosuppressants, or drugs with direct action on vascular reactivity (e.g., continuous use of nitrates).
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Systemic (cutaneous) microcirculatory reactivity.
Timeframe: up to 20 minutes
Trial details
NCT IDNCT07563725
SponsorNational Institute of Cardiology, Laranjeiras, Brazil